RxDoctor Payments Data

Steven Towle

Optometrist · Bismarck, NDNPI 1932197209

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Alcon at 35.9% of the total. Reporting peaked in 2021 at $317 and has fallen 85.6% since, to $46 in 2025.

$1,012in general payments, 2019–2025

Across 43 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$364
  • AbbVie$218
  • Aerie Pharmaceuticals, Inc.$190
  • Mallinckrodt Hospital Products Inc.$48
  • Dompe US, Inc.$43
  • Amgen$29
  • plus $120 from 6 others

What the payments were for

  • Food & beverage$1,00799%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,012 in reported general payments places this provider in the 75th percentile of 179 optometrist providers in North Dakota.

See all optometrist providers in North Dakota

Medicare billing

Part B allowed, 2024
$45,744
Medicare patients
319
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost28$18,485
RocklatanNetarsudil Mesylat/Latanoprost20$10,413
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$2,575
Travoprost12$2,084
Latanoprost121$1,406
Timolol Maleate87$1,033
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$420
ErythromycinErythromycin Base28$254
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim12$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$218$18,48528 claims
Aerie Pharmaceuticals, Inc.Rocklatan$190$10,41320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 179 optometrist providers in North Dakota.

Other optometrist in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →